The influence of recombinant human BMP-2 on bone-implant osseointegration: biomechanical testing and histomorphometric analysis.
The healing period for bone-implant osseointegration lasts 3-6 months or even longer. The aim of this study was to investigate whether osseointegration can be enhanced by the use of bone morphogenetic protein-2 (BMP-2). In the femurs of 8 Japanese white rabbits, 16 implants were applied with 1.0 mg recombinant human BMP-2 (rhBMP-2) as group A, and the other 16 implants without rhBMP-2 as group B. Calcein green 20 mg/kg and alizarin red 20 mg/kg were injected 4 and 8 weeks after implantation, respectively. At 12 weeks, the animals were killed. In 16 implant-bone blocks, binding strength was measured by pull-out test, and the extracted implants were observed under a scanning electronic microscope. The other blocks were analysed for percentage of marked bone adjacent to the implant surface by confocal laser scanning microscope. The pull-out strengths of group A were greater than that of group B (P<0.05). Scanning electronic microscopy (SEM) showed more calcified substances on the surface of the implants of group A than B. There was more marked bone around group A than B implants at 4 weeks (P<0.05) and 8 weeks (P<0.05). rhBMP-2 improves the quantity and quality of implant-bone osseointegration. Biomechanical testing and histomorphometric analysis are reliable methods to use in researching the implant-bone interface.
Lan
J
J
Department of Prosthodontics of Stomatological School of Wuhan University, Key Lab for Oral Biomedical Engineering of Ministry of Education, Wuhan, PR China.
Wang
Z F
ZF
Shi
B
B
Xia
H B
HB
Cheng
X R
XR
D000818:Animals; D000880:Anthraquinones; D001696:Biomechanical Phenomena; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D020099:Coated Materials, Biocompatible / Q000737:chemistry; D005269:Femur / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D005452:Fluoresceins; D005456:Fluorescent Dyes; D006801:Humans; D020007:Implants, Experimental; D019344:Lactic Acid / Q000737:chemistry; D008297:Male; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D016348:Osseointegration / Q000187:drug effects*; D011091:Polyesters; D011108:Polymers / Q000737:chemistry; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000494:pharmacology*; D013314:Stress, Mechanical; D013499:Surface Properties; D013997:Time Factors; D014025:Titanium / Q000737:chemistry; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects
D000880:Anthraquinones; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D020099:Coated Materials, Biocompatible; D005452:Fluoresceins; D005456:Fluorescent Dyes; D011091:Polyesters; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C083098:calcein green; C499469:recombinant human bone morphogenetic protein-2; D019344:Lactic Acid; C033616:poly(lactide); C010078:alizarin; D014025:Titanium